A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Thioureidobutyronitrile (Primary)
Indications Ovarian cancer
Focus Adverse reactions; Pharmacodynamics
Sponsors Innovation Pharmaceuticals

Most Recent Events

08 Feb 2018 Status changed from recruiting to completed, according to an Innovation Pharmaceuticals media release.
27 Dec 2017 Preliminary data from the first patients in this trial presented in an Innovation Pharmaceuticals media release.
14 Sep 2017 According to an iPharma media release, the company expects initial primary results in 4th quarter 2017.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight